Viridian Therapeutics Net Income 2014-2021 | VRDN

Viridian Therapeutics net income from 2014 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Viridian Therapeutics Annual Net Income
(Millions of US $)
2020 $-111
2019 $-42
2018 $-33
2017 $-27
2016 $-17
2015 $-11
2014 $-8
2013 $-2
Viridian Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-18
2021-03-31 $-18
2020-12-31 $-91
2020-09-30 $-5
2020-06-30 $-6
2020-03-31 $-8
2019-12-31 $-10
2019-09-30 $-11
2019-06-30 $-9
2019-03-31 $-12
2018-12-31 $-10
2018-09-30 $-9
2018-06-30 $-9
2018-03-31 $-5
2017-12-31 $-6
2017-09-30 $-6
2017-06-30 $-7
2017-03-31 $-7
2016-12-31 $-6
2016-09-30 $-4
2016-06-30 $-4
2016-03-31 $-4
2015-12-31 $-3
2015-09-30 $-3
2015-06-30 $-3
2015-03-31 $-3
2014-12-31 $-2
2014-09-30 $-2
2014-06-30 $-3
2014-03-31 $-1
2013-12-31 $-0
2013-09-30 $-1
2013-06-30 $-1
2013-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.159B $0.001B
Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48